Inhibikase Therapeutics (IKT) Times Interest Earned (2020 - 2022)
Historic Times Interest Earned for Inhibikase Therapeutics (IKT) over the last 3 years, with Q1 2022 value amounting to -$928119.2.
- Inhibikase Therapeutics' Times Interest Earned fell 41696255.1% to -$928119.2 in Q1 2022 from the same period last year, while for Dec 2022 it was -$3.6 million, marking a year-over-year decrease of 48909522.26%. This contributed to the annual value of -$741.16 for FY2021, which is 67316.52% down from last year.
- Inhibikase Therapeutics' Times Interest Earned amounted to -$928119.2 in Q1 2022, which was down 41696255.1% from -$31908.0 recorded in Q4 2021.
- In the past 5 years, Inhibikase Therapeutics' Times Interest Earned registered a high of -$52.08 during Q2 2020, and its lowest value of -$928119.2 during Q1 2022.
- In the last 3 years, Inhibikase Therapeutics' Times Interest Earned had a median value of -$222.54 in 2021 and averaged -$109939.3.
- Per our database at Business Quant, Inhibikase Therapeutics' Times Interest Earned crashed by 20598.01% in 2021 and then plummeted by 41696255.1% in 2022.
- Quarter analysis of 3 years shows Inhibikase Therapeutics' Times Interest Earned stood at -$168.21 in 2020, then crashed by 18869.2% to -$31908.0 in 2021, then tumbled by 2808.74% to -$928119.2 in 2022.
- Its Times Interest Earned was -$928119.2 in Q1 2022, compared to -$31908.0 in Q4 2021 and -$28478.0 in Q3 2021.